KalVista Pharmaceuticals Files 8-K with Material Agreement Details
Ticker: KALV · Form: 8-K · Filed: Apr 8, 2025 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, financials
TL;DR
KalVista Pharma dropped an 8-K on April 8th – material agreement, Reg FD, and financials filed. Check it out.
AI Summary
On April 8, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures and financial statements/exhibits. The company, formerly known as Carbylan Therapeutics, Inc., is incorporated in Delaware and based in Cambridge, MA.
Why It Matters
This filing provides crucial updates on significant agreements and financial information for KalVista Pharmaceuticals, impacting investor understanding of the company's current status and future direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant financial or operational risks and opportunities, requiring careful investor scrutiny.
Key Numbers
- 001-36830 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-0915291 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- April 8, 2025 (date) — Date of Report
- Carbylan Therapeutics, Inc. (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, MA (location) — Business Address City/State
FAQ
What is the nature of the material definitive agreement filed by KalVista Pharmaceuticals?
The 8-K filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
When was this 8-K report filed?
The report was filed on April 8, 2025.
What other information is included in this 8-K filing besides the material agreement?
The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
What was KalVista Pharmaceuticals' former company name?
KalVista Pharmaceuticals, Inc. was formerly known as Carbylan Therapeutics, Inc.
Where is KalVista Pharmaceuticals, Inc. incorporated and headquartered?
The company is incorporated in Delaware and its business address is in Cambridge, MA.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 8, 2025 regarding KalVista Pharmaceuticals, Inc. (KALV).